DK0519463T3 - Syntetiske, katalytiske oligonukleotider - Google Patents

Syntetiske, katalytiske oligonukleotider

Info

Publication number
DK0519463T3
DK0519463T3 DK92110298T DK92110298T DK0519463T3 DK 0519463 T3 DK0519463 T3 DK 0519463T3 DK 92110298 T DK92110298 T DK 92110298T DK 92110298 T DK92110298 T DK 92110298T DK 0519463 T3 DK0519463 T3 DK 0519463T3
Authority
DK
Denmark
Prior art keywords
formula
nucleotides
nucleotide
alkyl
oligonucleotide
Prior art date
Application number
DK92110298T
Other languages
Danish (da)
English (en)
Inventor
Giovanni Dr Paolella
Brian Dr Sproat
Angus Dr Lamond
Original Assignee
Europaeisches Lab F R Molekula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaeisches Lab F R Molekula filed Critical Europaeisches Lab F R Molekula
Application granted granted Critical
Publication of DK0519463T3 publication Critical patent/DK0519463T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
DK92110298T 1991-06-20 1992-06-17 Syntetiske, katalytiske oligonukleotider DK0519463T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4120406 1991-06-20
DE4216134A DE4216134A1 (de) 1991-06-20 1992-05-15 Synthetische katalytische oligonukleotidstrukturen

Publications (1)

Publication Number Publication Date
DK0519463T3 true DK0519463T3 (da) 1999-06-28

Family

ID=25904724

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92110298T DK0519463T3 (da) 1991-06-20 1992-06-17 Syntetiske, katalytiske oligonukleotider
DK97121976T DK0845476T3 (da) 1991-06-20 1992-06-17 Syntetiske katalytiske oligonukleotider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97121976T DK0845476T3 (da) 1991-06-20 1992-06-17 Syntetiske katalytiske oligonukleotider

Country Status (10)

Country Link
US (1) US5334711A (fr)
EP (3) EP1061085A3 (fr)
JP (3) JP3512818B2 (fr)
AT (2) ATE172468T1 (fr)
AU (1) AU658634B2 (fr)
CA (1) CA2071446C (fr)
DE (3) DE4216134A1 (fr)
DK (2) DK0519463T3 (fr)
ES (2) ES2155959T3 (fr)
PT (1) PT845476E (fr)

Families Citing this family (386)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US6041910A (en) * 1997-09-22 2000-03-28 Jervis B. Webb Company Baggage pusher device and system
PL169576B1 (pl) * 1990-10-12 1996-08-30 Max Planck Gesellschaft Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) * 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6204027B1 (en) * 1992-02-26 2001-03-20 University Of Massachusetts Worcester Ribozymes having 2′-O substituted nucleotides in the flanking sequences
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
US20030125270A1 (en) * 2000-12-18 2003-07-03 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5891684A (en) * 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5837542A (en) * 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US6323185B1 (en) * 1993-04-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-viral guanosine-rich oligonucleotides and method of treating HIV
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
FR2705099B1 (fr) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US5817635A (en) * 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
WO1995006731A2 (fr) * 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Acide nucleique enzymatique contenant un non-nucleotide
JPH09504297A (ja) * 1993-10-27 1997-04-28 リボザイム・ファーマシューティカルズ・インコーポレーテッド ２′−アミドおよび２′−ペプチド修飾オリゴヌクレオチド
AU687479B2 (en) 1993-11-08 1998-02-26 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5631359A (en) * 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5639647A (en) * 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US6639061B1 (en) * 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US5599706A (en) * 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
AU4412096A (en) * 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5672501A (en) * 1994-12-23 1997-09-30 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5705388A (en) * 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5663064A (en) * 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
US5910408A (en) * 1995-06-07 1999-06-08 The General Hospital Corporation Catalytic DNA having ligase activity
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
EP0871643A4 (fr) * 1995-07-19 2000-12-06 Aronex Pharmaceuticals Inc Oligonucleotides antiviraux riches en guanosine
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20040220128A1 (en) * 1995-10-26 2004-11-04 Sirna Therapeutics, Inc. Nucleic acid based modulation of female reproductive diseases and conditions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
CZ243498A3 (cs) * 1996-02-14 1999-09-15 Isis Pharmaceuticals, Inc. Oligonukleotidy s mezerou a modifikovaným cukrem
US6238917B1 (en) * 1996-04-02 2001-05-29 Commonwealth Scientific Industrial Research Organizaion Asymmetric hammerhead ribozymes
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
EP0946736B1 (fr) * 1996-12-13 2003-10-29 Chiron Corporation Procedes permettant d'exprimer des proteines heterologues dans la levure
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US20030186909A1 (en) * 1997-01-27 2003-10-02 Ribozyme Pharmaceuticals, Inc. Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6057156A (en) 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP0971944A4 (fr) * 1997-02-04 2005-01-26 Aronex Pharmaceuticals Inc Oligonucleotides antiviraux riches en guanosine formant des tetrades
US6159951A (en) * 1997-02-13 2000-12-12 Ribozyme Pharmaceuticals Inc. 2'-O-amino-containing nucleoside analogs and polynucleotides
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6280936B1 (en) 1997-06-09 2001-08-28 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6548657B1 (en) 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6300483B1 (en) * 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
US6183959B1 (en) 1997-07-03 2001-02-06 Ribozyme Pharmaceuticals, Inc. Method for target site selection and discovery
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
EP1030913A2 (fr) * 1997-09-22 2000-08-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Acides nucleiques catalyseurs a activite d'endonuclease
US6656731B1 (en) 1997-09-22 2003-12-02 Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid catalysts with endonuclease activity
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
WO1999054459A2 (fr) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
US6995259B1 (en) * 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
WO2000066780A2 (fr) * 1999-04-30 2000-11-09 University Of Florida Ribozymes fournis par virus adeno-associes pour la decouverte de fonctions geniques
AR025996A1 (es) 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
US6831171B2 (en) * 2000-02-08 2004-12-14 Yale University Nucleic acid catalysts with endonuclease activity
WO2005041859A2 (fr) 2003-04-30 2005-05-12 Sirna Therapeutics, Inc. Conjugues et compositions
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
WO2002081628A2 (fr) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050233329A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
US20080039414A1 (en) * 2002-02-20 2008-02-14 Sima Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2003525037A (ja) * 2000-02-11 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド Ｃｄ２０およびｎｏｇｏ遺伝子発現の調節および診断のための方法および試薬
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040009510A1 (en) * 2000-03-06 2004-01-15 Scott Seiwert Allosteric nucleic acid sensor molecules
US20030065155A1 (en) * 2000-03-06 2003-04-03 Nassim Usman Nucleic acid sensor molecules
US20020102694A1 (en) * 2000-03-31 2002-08-01 Ronald Breaker Nucleozymes with endonuclease activity
WO2002000174A2 (fr) 2000-06-28 2002-01-03 Corixa Corporation Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
US6686157B2 (en) 2000-06-30 2004-02-03 Molecular Staging Inc. Signal amplification with lollipop probes
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US6861222B2 (en) * 2000-11-09 2005-03-01 Yale University Nucleic acid detection using structured probes
JP2004532022A (ja) * 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
CA2446788A1 (fr) 2001-05-09 2002-11-14 Corixa Corporation Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
EP3231445A1 (fr) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugués et compositions pour la fourniture cellulaire
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050176665A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
WO2002097114A2 (fr) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Traitement a l'acide nucleique de maladies ou d'affections associees aux taux de ras, her2 et hiv
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) * 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
AU2002313699A1 (en) * 2001-07-20 2003-03-03 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US20030084473A1 (en) * 2001-08-09 2003-05-01 Valigen Non-transgenic herbicide resistant plants
WO2003057709A2 (fr) * 2001-10-19 2003-07-17 Sirna Therapeutics, Inc Methode et reactif de detection de proteines et de peptides
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070203333A1 (en) * 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050075304A1 (en) * 2001-11-30 2005-04-07 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002357240A1 (en) * 2001-12-14 2003-06-30 Yale University Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
CA2476755C (fr) 2001-12-17 2014-08-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
MXPA04007586A (es) 2002-02-06 2005-06-08 Vicor Technologies Inc Moleculas anti-infarto.
WO2003106476A1 (fr) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Inhibition d'une infection a enterocoques et de l'activite de la cytolysine induite par des acides nucleiques
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
EP1534729A2 (fr) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variantes du nedd4l associees a l'hypertension et au bourgeonnement viral
US20030195164A1 (en) * 2002-04-16 2003-10-16 Veli-Matti Kahari Novel ribozyme and its use
US20040018520A1 (en) * 2002-04-22 2004-01-29 James Thompson Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
US20030224435A1 (en) * 2002-05-16 2003-12-04 Scott Seiwert Detection of abused substances and their metabolites using nucleic acid sensor molecules
US7655790B2 (en) * 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US6989442B2 (en) * 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
AU2003300776A1 (en) * 2002-09-09 2004-05-25 Omeros Corporation G protein coupled receptors and uses thereof
JP2006500030A (ja) * 2002-09-20 2006-01-05 イェール ユニバーシティ リボスイッチ、その使用方法、ならびにリボスイッチとともに用いるための組成物
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
EP1620112A4 (fr) * 2003-04-17 2007-04-25 Univ Columbia Desmogleine 4, nouveau gene de la croissance des cheveux
US20050287668A1 (en) * 2003-11-04 2005-12-29 Cell Therapeutics, Inc. (Cti) RNA interference compositions and screening methods for the identification of novel genes and biological pathways
US20060019914A1 (en) * 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
EP1735009A4 (fr) * 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Agents arni ciblant le facteur de croissance de l'endothelium vasculaire (vegf)
JP4635046B2 (ja) * 2004-04-20 2011-02-16 マリナ・バイオテック・インコーポレーテッド 哺乳類の細胞における遺伝子発現を調節するための、二本鎖ｒｎａまたは二本鎖ハイブリッド核酸の送達を増強するための方法および組成物
EP1747022A4 (fr) 2004-04-23 2010-03-31 Univ Columbia Inhibition d'un arnm associe a une proteine du gene hairless (sans poil)
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP1846034A4 (fr) 2005-02-02 2010-11-10 Uab Research Foundation Agents et methodes associes a la reduction de la resistance aux agonistes des recepteurs de mort induisant l'apoptose
JP4528154B2 (ja) * 2005-02-25 2010-08-18 株式会社クボタ 田植機用の苗植付け機構
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
EP1863908B1 (fr) 2005-04-01 2010-11-17 Qiagen GmbH Transcription inverse et amplification d'arn avec degradation simultanee d'adn
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
US20100129288A1 (en) * 2005-06-28 2010-05-27 Elior Peles Gliomedin, Fragments Thereof and Methods of Using Same
WO2007002904A2 (fr) 2005-06-28 2007-01-04 Medtronic, Inc. Procedes et sequences permettant de supprimer de maniere preferentielle l'expression de la huntingtine mutee
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
EP1762627A1 (fr) 2005-09-09 2007-03-14 Qiagen GmbH Procédé pour l'activation d'acides nucléiques pour effectuer une réaction d'une polymérase
JP2009511018A (ja) * 2005-10-06 2009-03-19 エムセラックス，エルエルシー ワクチンとしての炭疽菌芽胞糖タンパク質に関する方法及び組成物
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2402435A3 (fr) 2005-10-14 2012-03-28 MUSC Foundation For Research Development Ciblage du PAX2 pour l'induction de l'immunité à la tumeur à médiation DEFB1 et le traitement contre le cancer
US8313901B2 (en) * 2005-12-21 2012-11-20 Yale University Methods and compositions related to the modulation of riboswitches
FI20055712A0 (fi) * 2005-12-29 2005-12-29 Wallac Oy Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
JP2009523418A (ja) 2006-01-12 2009-06-25 サイバス，エルエルシー Ｅｐｓｐｓ変異体
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
ES2544861T3 (es) * 2006-03-31 2015-09-04 Alnylam Pharmaceuticals Inc. Composiciones y métodos para inhibir la expresión del gen Eg5
EP2010226B1 (fr) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine
US8158782B2 (en) * 2006-05-05 2012-04-17 Wallac Oy Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
CA2893168C (fr) 2006-06-28 2017-11-07 Nucelis Inc. Melanges d'acides gras et leurs utilisations
US20100137440A1 (en) * 2006-09-11 2010-06-03 Yale University Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
AU2007297535C1 (en) 2006-09-21 2017-11-23 University Of Florida Research Foundation, Inc. Compositions and methods related to protein displacement therapy for myotonic distrophy
JP5876637B2 (ja) * 2006-10-18 2016-03-02 マリーナ バイオテック，インコーポレイテッド ニックまたはギャップの入った核酸分子およびそれらの使用
US20100062436A1 (en) 2006-10-31 2010-03-11 Noxxon Pharma Ag Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
WO2008136852A2 (fr) 2006-11-01 2008-11-13 University Of Rochester Méthodes et compositions se rapportant à la structure et à la fonction de apobec3g
CA2672297A1 (fr) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions et methodes de traitement de l'angiogenese pathologique et de la permeabilite vasculaire
US20100055782A1 (en) * 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
US20100055784A1 (en) * 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20100041140A1 (en) * 2007-03-02 2010-02-18 Mdrna, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
EP2121923A1 (fr) * 2007-03-02 2009-11-25 MDRNA, Inc. Composes d'acide nucleique permettant d'inhiber l'expression de gene de la famille erbb et utilisations de ceux-ci
EP2468864A1 (fr) * 2007-03-02 2012-06-27 Marina Biotech, Inc. Composés d'acides nucléiques pour l'inhibition de l'expression de gène de la famille VEGF et utilisations associées
CA2679387A1 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composes d'acide nucleique permettant d'inhiber l'expression de gene akt et utilisations de ceux-ci
WO2008109357A1 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène apob et utilisations de ceux-ci
CA2679342A1 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composes d'acide nucleique pour inhiber l'expression de gene hif1a et utilisations de ceux-ci
WO2008109362A1 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène vegf et utilisations de ceux-ci
ES2599632T3 (es) 2007-04-09 2017-02-02 University Of Florida Research Foundation, Inc. Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
EP2157982B1 (fr) 2007-05-04 2014-12-17 Marina Biotech, Inc. Lipides d'acides aminés et leurs utilisations
WO2008142693A2 (fr) * 2007-05-22 2008-11-27 Yeda Research And Development Co. Ltd. Régulation de la myélination par des molécules de type nectine (necl)
EP2164994A4 (fr) * 2007-05-29 2010-07-21 Univ Yale Inc Procédés et compositions liés à des ribointerrupteurs qui régulent l'épissage alternatif et le traitement d'arn
EP2426219A1 (fr) * 2007-05-29 2012-03-07 Yale University Riborégulateurs (riboswitches) et procédés et compositions à utiliser avec les riborégulateurs
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8183221B2 (en) * 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
CA2701624C (fr) 2007-10-05 2019-08-20 Cibus International Lp Genes d'acetohydroxyacide synthase mutes chez brassica
WO2010070380A2 (fr) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Compositions doc1 et méthodes de traitement du cancer
EP4074344A1 (fr) 2007-12-04 2022-10-19 Arbutus Biopharma Corporation Lipides de ciblage
EA201070649A1 (ru) * 2007-12-27 2011-06-30 Сибас Ойлз Интернэшнл Л.П. Смеси алкиловых эфиров жирных кислот и их применение
US20110117125A1 (en) 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
EP2262489A2 (fr) * 2008-02-28 2010-12-22 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Nano-particles creux et leur utilisations
AU2009221775B2 (en) * 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
WO2009123764A2 (fr) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions et utilisation d'inhibiteurs d'epas1
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
EP2288922B1 (fr) 2008-05-08 2016-08-17 University of Utah Research Foundation Récepteurs sensoriels pour fatigue et douleur chroniques et leurs utilisations
EP3260549A1 (fr) * 2008-05-23 2017-12-27 Nucelis LLC Production de squalène au moyen de la levure
US20110212021A1 (en) 2008-05-30 2011-09-01 Slack Frank J Targeted oligonucleotide compositions for modifying gene expression
US20100015708A1 (en) * 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
EP2633864A1 (fr) 2008-07-25 2013-09-04 The Regents of the University of Colorado Inhibiteurs de clip et procédés de modulation de la fonction immune
EP2341924A4 (fr) 2008-10-02 2013-01-23 David Gladstone Inst Méthodes de traitement d une infection par le virus de l hépatite c
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
US20100112042A1 (en) 2008-10-16 2010-05-06 Mdrna, Inc. Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
ES2631507T3 (es) 2008-10-29 2017-08-31 China Synthetic Rubber Corporation Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
EP3699172A3 (fr) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
WO2010065617A1 (fr) 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 en tant que cible thérapeutique dans les maladies cardiaques
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
US20100215660A1 (en) 2009-02-23 2010-08-26 Sarwar Hashmi Kruppel-like factors and fat regulation
ES2573981T3 (es) 2009-04-10 2016-06-13 Association Institut De Myologie Oligonucleótidos antisentido de triciclo-ADN, composiciones, y métodos para el tratamiento de enfermedades
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CA3045126A1 (fr) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Procedes d'administration d'oligonucleotides en direction de cellules immunitaires
KR20180094137A (ko) 2009-05-05 2018-08-22 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
US8158601B2 (en) 2009-06-10 2012-04-17 Alnylam Pharmaceuticals, Inc. Lipid formulation
WO2011000107A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
WO2011039646A2 (fr) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Ciblage de particules d'administration de gène de papillomavirus
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
ES2625154T3 (es) 2009-11-23 2017-07-18 Nucelis Llc Métodos y composiciones para producir escualeno empleando levaduras
CA2783372C (fr) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions utilisees pour l'administration d'acides nucleiques
ES2749426T3 (es) 2009-12-18 2020-03-20 Univ British Columbia Métodos y composiciones para administración de ácidos nucleicos
KR20120125357A (ko) 2010-02-10 2012-11-14 노파르티스 아게 근육 성장을 위한 방법 및 화합물
AU2011215753B2 (en) * 2010-02-11 2015-09-03 Nanostring Technologies, Inc. Compositions and methods for the detection of small RNAs
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2550361B1 (fr) 2010-03-25 2017-02-08 The J. David Gladstone Institutes Compositions et procédés pour traiter des troubles neurologiques
WO2011120023A1 (fr) 2010-03-26 2011-09-29 Marina Biotech, Inc. Composés d'acide nucléique pour inhiber l'expression de gène de survivine et utilisations de ceux-ci
WO2011133584A2 (fr) 2010-04-19 2011-10-27 Marina Biotech, Inc. Composés de type acide nucléique pour inhiber l'expression du gène hras et leurs utilisations
ES2911185T3 (es) 2010-04-23 2022-05-18 Univ Florida Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
WO2011139710A1 (fr) 2010-04-26 2011-11-10 Marina Biotech, Inc. Composés d'acide nucléique ayant des monomères à conformation restreinte et leurs utilisations
WO2011139843A2 (fr) 2010-04-28 2011-11-10 Marina Biotech, Inc. Compositions multi-siarn pour la réduction de l'expression génique
WO2012006506A1 (fr) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Genès, enzymes et flux constituant des cibles métaboliques pour la thérapie contre le cancer
WO2012016184A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour la délivrance d'agents actifs
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
UA112969C2 (uk) 2010-08-03 2016-11-25 Сібас Юс Ллс Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх)
US20120122223A1 (en) 2010-08-03 2012-05-17 Cibus Us Llc Mutated protoporphyrinogen ix oxidase (ppx) genes
WO2012027206A1 (fr) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. Agents à base d'arni à un seul brin contenant une séquence intercalaire interne ne correspondant pas à un acide nucléique
SG10201508118WA (en) 2010-09-30 2015-11-27 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
AU2012207606B2 (en) 2011-01-11 2017-02-23 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
EP2753631A1 (fr) 2011-09-07 2014-07-16 Marina Biotech, Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
WO2013049328A1 (fr) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
PT2766393T (pt) 2011-10-14 2018-10-15 Hoffmann La Roche Anticorpos anti-htra1 e métodos de utilização
DK2790736T3 (en) 2011-12-12 2018-05-07 Oncoimmunin Inc In vivo delivery of oligonucleotides
WO2013101645A1 (fr) 2011-12-27 2013-07-04 The J. David Gladstone Institutes Compositions et procédés pour la régulation du métabolisme du glucose
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
KR20220045089A (ko) 2012-02-24 2022-04-12 아뷰터스 바이오파마 코포레이션 트리알킬 양이온성 지질 및 그의 사용 방법
KR101520383B1 (ko) 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
EA037142B1 (ru) 2013-03-14 2021-02-10 Сибас Юс Ллс Мутированные гены алленоксидсинтазы 2 (aos2)
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
KR102451570B1 (ko) 2013-03-15 2022-10-06 시버스 유에스 엘엘씨 올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
DK2966984T3 (da) 2013-03-15 2022-04-25 Cibus Us Llc Målrettet genmodifikation under anvendelse af oligonukleotid-medieret genreparation
CN105283561A (zh) 2013-04-04 2016-01-27 佐治亚州立大学研究基金会公司 使用纳米粒子辅助信号放大的rna微芯片检测
EP3019200B1 (fr) 2013-07-11 2022-03-23 Alnylam Pharmaceuticals, Inc. Conjugués d'oligonucléotides et de ligands, et procédé pour leur préparation
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
PT3046583T (pt) 2013-09-18 2019-05-30 Aura Biosciences Inc Conjugados de partículas semelhantes a vírus para o tratamento de tumores
WO2015074010A2 (fr) 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions et méthode de régénération pulmonaire
RS65213B1 (sr) 2014-03-14 2024-03-29 Cibus Us Llc Postupci i kompozicije za povećanje efikasnosti ciljane modifikacije gena korišćenjem reparacije gena posredovane oligonukleotidima
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
WO2016061131A1 (fr) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions et procédés pour réactiver un virus d'immunodéficience latent
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
EP3331536A4 (fr) 2015-08-03 2019-03-27 The Regents of The University of California Compositions et procédés pour moduler l'activité d'abhd2
MX2018004509A (es) 2015-10-30 2018-08-01 Genentech Inc Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2018005468A (es) 2015-10-30 2018-11-09 The Us Secretary Department Of Health And Man Services Terapia dirigida contra el cáncer.
EA201891629A1 (ru) 2016-02-09 2019-03-29 Сибас Юс Ллс Способы и композиции для повышения эффективности нацеленной модификации генов с применением опосредуемой олигонуклеотидами репарации генов
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45468A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques myc et utilisations
MA45471A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
WO2017205506A1 (fr) 2016-05-24 2017-11-30 Emory University Particules conjuguées à des polymères à base de nucléobases clivant l'arn et leurs utilisations dans la prise en charge des troubles inflammatoires
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
CA3033327A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Proteines de fusion cas9-recombinase programmables et utilisations associees
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
CN110381980A (zh) 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 核酸-多肽组合物以及诱导外显子跳读的方法
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019023680A1 (fr) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
WO2019079347A1 (fr) 2017-10-16 2019-04-25 The Broad Institute, Inc. Utilisations d'éditeurs de bases adénosine
SG11202005022YA (en) 2017-12-06 2020-06-29 Avidity Biosciences Inc Compositions and methods of treating muscle atrophy and myotonic dystrophy
AU2019207703A1 (en) 2018-01-09 2020-07-16 Cibus Europe B.V. Shatterproof genes and mutations
CN113508136A (zh) 2018-12-21 2021-10-15 艾维迪提生物科学公司 抗转铁蛋白受体抗体及其用途
WO2020191239A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotiques
CA3150458A1 (fr) 2019-08-14 2021-02-18 Acuitas Therapeutics, Inc. Nanoparticules lipidiques ameliorees pour l'administration d'acides nucleiques
CN115666589A (zh) 2020-03-19 2023-01-31 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
AU2021241682A1 (en) 2020-03-27 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
WO2022097157A2 (fr) 2020-11-09 2022-05-12 1E Therapeutics, Ltd. Méthodes de traitement ou de prévention d'infections bactériennes faisant appel à une séquence catalytique
WO2022130388A2 (fr) 2020-12-18 2022-06-23 Yeda Research And Development Co. Ltd. Compositions destinées à être utilisées dans le traitement d'une haplo-insuffisance chd2 et procédés d'identification de celles-ci
EP4267741A2 (fr) 2020-12-28 2023-11-01 1E Therapeutics, Ltd. Zones cibles de l'arnm p21 pour le silençage
KR20230133859A (ko) 2020-12-28 2023-09-19 1이 테라퓨틱스 엘티디. p21 mRNA 표적화 DNA자임
AU2022249318A1 (en) 2021-03-31 2023-10-12 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
EP4337263A1 (fr) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions et méthodes de modulation de l'activité du facteur 5 de régulation de l'interféron (irf-5)
EP4337261A2 (fr) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions et procédés de modulation de l'épissage d'arnm
AU2022271873A1 (en) 2021-05-10 2024-01-04 Entrada Therapeutics, Inc. Compositions and methods for intracellular therapeutics
WO2022271818A1 (fr) 2021-06-23 2022-12-29 Entrada Therapeutics, Inc. Composés antisens et méthodes de ciblage de répétitions de cug
IL310547A (en) 2021-08-05 2024-03-01 Sanegene Bio Usa Inc Alkyl substituted ribose derivatives in the '1 position and methods of use
US11912779B2 (en) 2021-09-16 2024-02-27 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
US20230241224A1 (en) 2021-09-22 2023-08-03 Sanegene Bio Usa Inc. 2'-alkyl or 3'- alkyl modified ribose derivatives and methods of use
US20230227480A1 (en) 2021-10-05 2023-07-20 Sanegene Bio Usa Inc. Polyhydroxylated cyclopentane derivatives and methods of use
WO2023144798A1 (fr) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Lipides cationiques ionisables pour nanoparticules lipidiques
WO2023144792A1 (fr) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Conjugués poly(alkyloxazoline)-lipide et particules lipidiques les contenant
WO2023164464A1 (fr) 2022-02-22 2023-08-31 Sanegene Bio Usa Inc. Dérivés de ribonucléotides carbocycliques modifiés en position 5' et procédés d'utilisation
WO2024015796A1 (fr) 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Dérivés du ribose modifié en 2' optimisés et procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
CA1340323C (fr) * 1988-09-20 1999-01-19 Arnold E. Hampel Catalyseur d'arn pour le clivage de sequences specifiques d'arn
DE3928900A1 (de) 1989-08-31 1991-03-07 Europ Lab Molekularbiolog Neue nucleotidderivate, ihre herstellung und ihre verwendung
NO904633L (no) * 1989-11-09 1991-05-10 Molecular Diagnostics Inc Amplifikasjon av nukleinsyrer ved transkriberbar haarnaalsprobe.
US5215899A (en) * 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription

Also Published As

Publication number Publication date
EP0519463B1 (fr) 1998-10-21
EP0845476A2 (fr) 1998-06-03
JP2004123754A (ja) 2004-04-22
EP1061085A2 (fr) 2000-12-20
EP0845476A3 (fr) 1998-06-10
ATE199725T1 (de) 2001-03-15
EP0519463A1 (fr) 1992-12-23
AU1824992A (en) 1992-12-24
EP0845476B1 (fr) 2001-03-14
AU658634B2 (en) 1995-04-27
DE4216134A1 (de) 1992-12-24
JP4027305B2 (ja) 2007-12-26
CA2071446C (fr) 1999-09-14
EP1061085A3 (fr) 2003-08-13
DE59209895D1 (de) 2001-04-19
CA2071446A1 (fr) 1992-12-21
JP3512818B2 (ja) 2004-03-31
DE59209531D1 (de) 1998-11-26
JPH06128284A (ja) 1994-05-10
ES2124712T3 (es) 1999-02-16
JP2001069972A (ja) 2001-03-21
ATE172468T1 (de) 1998-11-15
US5334711A (en) 1994-08-02
ES2155959T3 (es) 2001-06-01
PT845476E (pt) 2001-07-31
DK0845476T3 (da) 2001-06-25

Similar Documents

Publication Publication Date Title
DK0845476T3 (da) Syntetiske katalytiske oligonukleotider
CA2071536C (fr) Formation de la triple helice de l'adn dans les traitements a base d'oligonucleotides
DE69433626D1 (de) N-2 substituierte purine
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
IL100298A (en) 3(-(2()-amino- or thiol- modified, fluorescent dye- coupled nucleosides, nucleotides and oligonucleotides, and a process for the preparation and the use thereof
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
EP0693123A1 (fr) Oligonucleotides modifies ayant une activite antigrippe amelioree
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
DK0519053T3 (da) Nucleinsyreamplifikation med DNA-afhængig RNA-polymeraseaktivitet hos RNA-replicaser
Ling Pyrimidine Sequences from the DNA of Bacteriophages fd, fl, and ϕX174
ATE318617T1 (de) Synthetische oligonukleotide als erythroid differenzierungserreger
ES2196157T3 (es) Oligonucleotidos especificos para el virus de la hepatitis c.
SE9804298D0 (sv) New medical use
Shinozuka et al. Bi-functional labelling of DNA with tris (2-aminoethyl) amine-derived novel fluorescent agent
ATE264864T1 (de) Verbesserte chimäre oligonukleotidvektoren
AU7425800A (en) Single stranded oligonucleotides, probes, primers and method for detecting spirochetes
ATE342370T1 (de) Neuartige, aliphatische acyltransferase-gene
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler
DE69536047D1 (de) MN-Gen und -Protein
JPS6426594A (en) Nucleotides and antitumor agent
NZ515315A (en) Blocked nucleotides, removable by monochromatic light, for use in nucleic acid sequence analysis